Mount Elbrus 100 people to be attempting the summit via this route each day. Winter ascents are rare, and are usually undertaken only by very experienced climbers. Elbrus is notorious for its brutal winter weather, and summit attempts are few and far between. The climb is not technically difficult, but it is physically arduous because of the elevations and the frequent strong winds. The average annual death toll on Elbrus is 15–30, primarily due to "many unorganized and poorly equipped" attempts to summit the mountain. Since 1986, Elbrus has been incorporated into Prielbrusye National Park, one of the Protected areas of Russia.
MT-45 States the DEA placed MT-45 in Schedule 1 of the Controlled Substance Act. This took effect January 12, 2018. MT-45 MT-45 (IC-6) is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-(1,2-diphenylethyl)piperazine derivative, which is structurally unrelated to most other opioid drugs. Racemic MT-45 has around 80% the potency of morphine, with almost all opioid activity residing in the (S) enantiomer (the opposite stereochemistry from the related drug lefetamine). It has been used as a lead compound from which a large family of potent opioid drugs have been developed, including full agonists,